Vanguard Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$74.7M Buy
2,974,139
+217,369
+8% +$5.92M ﹤0.01% 1693
2026
Q2
$74.4M Buy
2,756,770
+302,407
+12% +$8.3M ﹤0.01% 1716
2026
Q1
$66.5M Buy
+2,454,363
New +$72M ﹤0.01% 1692

Other funds holding MLYS

Vanguard Capital Management's MLYS Position: Q3 2026 in Review

Vanguard Capital Management increased its Mineralys Therapeutics (MLYS) stake by 7.9% in Q3 2026, buying an estimated $5.92M and bringing the position to 2,974,139 shares worth $74.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

Vanguard Capital Management first reported a position in MLYS in Q1 2026 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Vanguard Capital Management held 2,974,139 shares of Mineralys Therapeutics worth $74.7M as of Q3 2026.
  • Vanguard Capital Management bought 217,369 Mineralys Therapeutics shares in Q3 2026, an estimated $5.92M.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1693 holding.
  • Vanguard Capital Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.